{"cursor":"2606","size":15,"audio":[],"currentlang":"en","article":"\n\n{{Infobox company |name = Access Pharmaceuticals, Inc. |logo = |type = Publicly\ntraded |genre = |foundation =  |founder = |Head\nOffice = |location_city = Dallas, Texas |location_country = USA |location =  |locations =  |origins =\n|key_people = |area_served = |industry = Biomedicine |products = MuGard\n|services = |revenue = |operating_income = |net_income = |num_employees =\n|parent = |divisions = |subsid = |owner = |slogan = |homepage =\nhttp://www.accesspharma.com |dissolved = |footnotes = |intl =  }}\n\n'Access Pharmaceuticals, Inc.' is a biopharmaceutical company based in Dallas,\nTexas. [http://topics.nytimes.com/top/news/business/companies/access-\npharmaceuticals-inc/index.html Company profile at the New York Times, date March\n20, 2009] It uses nanotechnology to modify existing medications to improve\ntheir efficacy and tolerance.\n\nAs of June 2008, Access has one product approved by the Food and Drug\nAdministration (FDA), namely [[MuGard]] for the management of oral\nmucositis. In September 2010, Access received its first U.S.\npurchase order for [[MuGard]] and as of fall 2010 continued to receive more and\nmore prescriptions for the product. Also, two products are in clinical trials,\nProLindac, a drug that contains the DACH-platinum oxaliplatin (an anti-ovarian\ncancer agent), [http://dx.doi.org/10.1039/C0DT00292E The status of platinum\nanticancer drugs in the clinic and in clinical trials] Dalton Transactions,\n2010, 39, 8113-8127 and a product with phenylbutyrate, a HDAC inhibitor.\n\nIn 2009 the company reported on preclinical studies of its agent Angiolix, a\nmonoclonal antibody that binds to lactadherin and inhibits\nangiogenesis. [http://www.medicalnewstoday.com/articles/136722.php Angiolix\nResults]\n","linknr":115,"url":"Access_Pharmaceuticals,_Inc.","recorded":1362553344,"links":12,"instances":[],"pdf":[],"categories":["Biotechnology companies of the United States","Companies based in Dallas, Texas"],"headings":["References","External links"],"image":["//upload.wikimedia.org/wikipedia/en/thumb/6/6c/Wiki_letter_w.svg/40px-Wiki_letter_w.svg.png","//bits.wikimedia.org/static-1.21wmf10/skins/vector/images/search-ltr.png?303-4","//bits.wikimedia.org/images/wikimedia-button.png","//bits.wikimedia.org/static-1.21wmf10/skins/common/images/poweredby_mediawiki_88x31.png"],"tags":[],"members":[],"related":["Dallas,_Texas","USA","Biomedicine","Biopharmacy","Dallas","Texas","The_New_York_Times","Nanotechnology","Medication","Efficacy","Drug_tolerance","Food_and_Drug_Administration","Mucositis","Clinical_trial","DACH-platinum","Oxaliplatin","Phenylbutyrate","HDAC_inhibitor","Monoclonal_antibody","Lactadherin","Angiogenesis"]}